The results of the interim analysis of PHranceSCa Study, a clinical trial that is underway in 32 hospital centers from 12 countries, among which Hospital da Luz Lisboa, were presented in the monothematic annual congress of breast cancer of the European Society of Oncology (ESMO), this year held virtually on 23 and 24 May, due to the covid-19 pandemics. Catarina Pulido , oncologist integrating the Oncology Department from Hospital da Luz Lisboa , is the main researcher of the trial at Hospital da Luz Lisboa and was co-author of the oral communication. The PHranceSCa Study is a randomized and unconcealed clinical trial, that intends to assess the preference and satisfaction of patients with HER2 positive breast cancer in early stage, treated with an innovative combination of pertuzumab and trastuzumab in a subcutaneous fixed-dose or with the same drugs but intravenously. The researchers of the PHranceSCa study observed that 82% of patients preferred the subcutaneous formulation to the intravenous treatment. The main reasons are the quickness and comfort of administration by this means: 90% of patients were satisfied or highly satisfied with the subcutaneous formulation and 84% preferred to complete their treatment with a subcutaneous combination, that was in general well tolerated and with a safety profile consistent with the intravenous formulation. Presently, a primary analysis of the study is under preparation, to be published by the end of 2020, and of which Catarina Pulido is also co-author, representing Hospital da Luz Lisboa. Including over 25 thousand members, ESMO is the main European organization in medical oncology, representing specialists from around 160 countries all over the world, and is a reference in terms of education and information in the area. “Results of an interim analysis of the PHranceSCa Study”
